Literature DB >> 32521494

Abscopal effect in radioimmunotherapy.

Milad Ashrafizadeh1, Bagher Farhood2, Ahmed Eleojo Musa3, Shahram Taeb4, Abolhassan Rezaeyan5, Masoud Najafi6.   

Abstract

Abscopal effect is an interesting phenomenon in radiobiology that causes activation of immune system against cancer cells. Traditionally, this phenomenon was known as a suppressor of non-irradiated tumors or metastasis. However, it can be used as a stimulator of the immune system against primary tumor during radiotherapy. Immunotherapy, a novel tumor therapy modality, also triggers immune system against cancer. To date, some immunotherapy types have been developed. However, immune checkpoint blockade is a more common modality and some drugs have been approved by the FDA. Studies have shown that radiotherapy or immunotherapy administered alone have low efficiency for tumor control. However, their combination has a more potent anti-tumor immunity. For this aim, it is important to induce abscopal effect in primary tumors, and also use appropriate drugs to target the mechanisms involved in the exhaustion of cytotoxic CD8+T lymphocytes (CTLs) and natural killer (NK) cells. Among the different radiotherapy techniques, stereotactic body radiation therapy (SBRT) with some few fractionations is the best choice for inducing abscopal effect. On the other hand, programmed cell death 1 (PD-1) is known as one of the best targets for triggering anti-tumor immunity. This combination is known as the best choice among various strategies for radioimmunotherapy. However, there is the need for other strategies to improve the duration of immune system's activity within tumor microenvironment (TME). In this review, we explain the cellular and molecular mechanisms behind abscopal effect by radiotherapy and evaluate the molecular targets which induce potent anti-tumor immunity.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Abscopal Effect; Immunotherapy; Programmed Cell Death 1 (PD-1); Radioimmunotherapy; Stereotactic Body Radiation Therapy (SBRT)

Mesh:

Year:  2020        PMID: 32521494     DOI: 10.1016/j.intimp.2020.106663

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  12 in total

Review 1.  Mechanisms of cancer cell killing by metformin: a review on different cell death pathways.

Authors:  Xiao-Yu Wu; Wen-Wen Xu; Xiang-Kun Huan; Guan-Nan Wu; Gang Li; Yu-Hong Zhou; Masoud Najafi
Journal:  Mol Cell Biochem       Date:  2022-06-30       Impact factor: 3.396

Review 2.  Current emerging MRI tools for radionecrosis and pseudoprogression diagnosis.

Authors:  Lucia Nichelli; Stefano Casagranda
Journal:  Curr Opin Oncol       Date:  2021-11-01       Impact factor: 3.915

3.  Serum Proteomics in Patients with Head and Neck Cancer: Peripheral Blood Immune Response to Treatment.

Authors:  Thorsteinn Astradsson; Felix Sellberg; Ylva Tiblom Ehrsson; Karl Sandström; Göran Laurell
Journal:  Int J Mol Sci       Date:  2022-06-04       Impact factor: 6.208

Review 4.  Targeting of cancer cell death mechanisms by resveratrol: a review.

Authors:  Xiao Fu; Mu Li; Cuilian Tang; Zezhi Huang; Masoud Najafi
Journal:  Apoptosis       Date:  2021-09-25       Impact factor: 4.677

Review 5.  Advances in Hypofractionated Irradiation-Induced Immunosuppression of Tumor Microenvironment.

Authors:  Yuxia Wang
Journal:  Front Immunol       Date:  2021-01-25       Impact factor: 7.561

Review 6.  Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.

Authors:  Somayeh Vafaei; Angelina O Zekiy; Ramadhan Ado Khanamir; Burhan Abdullah Zaman; Arman Ghayourvahdat; Hannaneh Azimizonuzi; Majid Zamani
Journal:  Cancer Cell Int       Date:  2022-01-03       Impact factor: 5.722

7.  Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review.

Authors:  María Rodríguez Plá; Diego Dualde Beltrán; Eduardo Ferrer Albiach
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

Review 8.  A Patient-Level Data Meta-analysis of the Abscopal Effect.

Authors:  Steven J Hatten; Eric J Lehrer; Jenn Liao; Congzhou M Sha; Daniel M Trifiletti; Shankar Siva; Sean M McBride; David Palma; Sheldon L Holder; Nicholas G Zaorsky
Journal:  Adv Radiat Oncol       Date:  2022-03-03

9.  Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study.

Authors:  Ke Cheng; Yuqing Wang; Ye Chen; Jingjie Zhu; Xiaohui Qi; Yachen Wang; Yanqiu Zou; Qiuhan Lu; Zhiping Li
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

Review 10.  Radiotherapy combined with immunotherapy: the dawn of cancer treatment.

Authors:  Zengfu Zhang; Xu Liu; Dawei Chen; Jinming Yu
Journal:  Signal Transduct Target Ther       Date:  2022-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.